Related Experiment Videos
Dexmedetomidine: a novel sedative-analgesic agent.
R Gertler1, H C Brown, D H Mitchell
1Department of Anesthesiology and Pain Management, Baylor University Medical Center, Dallas, Texas 75246, USA. Ralph_Gertler10@excite.com
Proceedings (Baylor University. Medical Center)
|December 22, 2005
Summary
Alpha2-adrenoceptor agonists like dexmedetomidine offer perioperative benefits including sedation, analgesia, and reduced anesthetic needs. These agents may help manage myocardial ischemia and pain, with potential for improved side effect profiles in newer drugs.
Area of Science:
- Anesthesiology and Pharmacology
- Cardiovascular Research
Background:
- Alpha2-adrenoceptor agonists, starting with clonidine, have expanded clinical applications.
- Dexmedetomidine, a newer agent, is used for short-term sedation (<24 hours).
Purpose of the Study:
- To provide background on the properties and applications of dexmedetomidine.
- To review the benefits and expanding roles of alpha2-adrenoceptor agonists in perioperative care.
Main Methods:
- Review of existing literature on alpha2-adrenoceptor agonists.
- Focus on dexmedetomidine's clinical use and effects.
Main Results:
- Alpha2-adrenoceptor agonists decrease sympathetic tone, attenuating neuroendocrine and hemodynamic responses.
- They reduce anesthetic and opioid requirements, providing sedation and analgesia while preserving psychomotor function.
- Potential benefits for perioperative myocardial ischemia prophylaxis and adjuvant treatment, with expanding roles in pain management and regional anesthesia.
Conclusions:
- Alpha2-adrenoceptor agonists offer significant advantages in perioperative settings.
- Dexmedetomidine represents a valuable tool for short-term sedation.
- Development of more selective agents may enhance perioperative anesthesia and analgesia strategies.